The Department of Defense's Defense Health Agency awarded a $1,774,998 Project Grant (CFDA 12.420 - Military Medical Research and Development) to the Coriell Institute for Medical Research, Inc. to study the role of exosomal galectin-3 in stromal activation and immunosuppression in advanced gastric adenocarcinoma. The three-year award, starting on September 30, 2024, will enable Coriell to conduct innovative biomedical research on this critical area of cancer biology. As a leading non-profit biomedical research center, Coriell frequently partners with federal agencies and academic institutions to advance scientific understanding of human diseases through genomics and cell biology expertise. This Project Grant award further demonstrates Coriell's capability to deliver specialized biospecimen services and genetic research to support the Defense Health Agency's military medical research priorities.
Generated 3/4/25, 8:50 AM